RJFSA
ECYT

Raymond James Financial Services Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-17,070
Closed -$303K – 2949
2018
Q3 		$303K Sell
17,070
-2,528
-13% -$43.4K ﹤0.01% 2275
2018
Q2 		$270K Buy
+19,598
New +$233K ﹤0.01% 2309

Other funds holding ECYT

OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
CA
Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Raymond James Financial Services Advisors's ECYT Position: Q4 2018 in Review

Raymond James Financial Services Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 17,070 shares — an estimated $303K sold.

Raymond James Financial Services Advisors first reported a position in ECYT in Q2 2018 and held it in 2 quarters. The position peaked at $303K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • Raymond James Financial Services Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 17,070 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $303K.
  • Raymond James Financial Services Advisors first reported a position in Endocyte, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Endocyte, Inc. Common Stock position peaked at $303K in Q3 2018.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.